EOLS NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Evolus Inc · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 5.84 USD
-2.3% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 6.5% above the Trend Line and sits at 36.1% of its 52-week range. The latest completed week returned -2.3%, after a -15.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 50/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 2d.

Setup score 24 out of 100
Latest Close 5.84 USD 31 Jul 2026
1W Return -2.3% latest completed week
4W Return -15.4% short-term follow-through
12W Return -8.2% quarterly tape
Trend Breadth 11.5% 6 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 6-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 43.51% based on similar historical setup states.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -2.3% Latest completed week; four-week move -15.4%. Indicator stack 27/50 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.51% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 50/100 conviction; expected move 27.2%. News sentiment 53/100 51 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 6.5% above the Trend Line and sits at 36.1% of its 52-week range. The latest completed week returned -2.3%, after a -15.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.6612-week average 0.42

12-week confirmation

Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.66Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -15.4% over four weeks, -8.2% over 12 weeks, and -36.2% over one year. The current trend has remained active for 6 consecutive weeks.

Performance by holding period

1W-2.3%
4W-15.4%
12W-8.2%
26W24.5%
52W-36.2%
Active trend streak6 weeks
Active weeks in one year6
Trend breadth11.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.32Latest activity-pressure read.
Pressure change-72.1%Four-week change in activity pressure.
Leadership-11.62Latest relative-leadership reading.
RS change-117.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 76% Model confidence 73%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength62/100Blend of value, momentum, and quality. Underlying universe rank 39; rank 1 is best.
Value55/100Relative valuation strength. Underlying universe rank 46; rank 1 is best.
Quality54/100Profitability and accounting quality. Underlying universe rank 47; rank 1 is best.
Momentum55/100Medium-term price momentum. Underlying universe rank 46; rank 1 is best.
Growth55/100Revenue and earnings growth. Underlying universe rank 46; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
1.3x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-5.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
65.5%
Gross profit retained from each unit of revenue.
Operating margin
-7.7%
Operating profit retained from revenue.
Free-cash-flow margin
-9.4%
Free cash flow generated from revenue.
Return on invested capital
-20.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
9.6%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-8.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

EOLS shows volatility options pressure with a 50/100 conviction score, put-call volume ratio of 0.12, expected move of 27.2%, and Sharemaestro trend signal active.

Conviction50/100
Expected move27.2%
Put/call volume0.12
Pressure90
Speculation1
Volatility96
Trend agreement8
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 51 relevant articles.

13 positive · 32 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move27.2%Nearest-chain priced movement where available.
52-week drawdown-37.5%Distance below the 52-week high.
13-week volatility7.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+28.6%Week of 6 Mar.
Worst week-13.6%Week of 27 Mar.
Latest week-2.3%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains6
Flat weeks0
Modest losses4
Sharp losses8
Recent vol7.6%13-week weekly-return volatility.
Base vol9.7%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew6.8% / -7.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape28/100

Trend, activity pressure, participation, and risk combine to a 28/100 tape read.

 Indicator analysis54/100

Latest 12-week confirmation: trend 6/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.66; No reversal markers Next-Week ExpectancyNegative 43.51%

Next-week expectancy is negative with a 43.51% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors56/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 48; Small Cap Core rank 51 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options37/100

EOLS shows volatility options pressure with a 50/100 conviction score, put-call volume ratio of 0.12, expected move of 27.2%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 27.2% Sentiment53/100

Weighted news tone is neutral across 51 relevant articles.

Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis Insiders50/100

No recent insider transaction evidence is stored.

 Earnings2d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20265.84 USD-2.3%5.48 USD9.92 USD0.32-11.623.1MOn
24 Jul 20265.98 USD4.4%5.51 USD9.95 USD0.68-10.453.0MOn
17 Jul 20265.73 USD-13.3%5.54 USD9.97 USD1.02-16.904.7MOn
10 Jul 20266.61 USD-4.2%5.59 USD9.98 USD1.21-9.574.1MOn
3 Jul 20266.90 USD-3.2%5.60 USD9.99 USD1.15-5.342.4MOn
26 Jun 20267.13 USD7.5%5.60 USD9.99 USD1.16-2.644.1MOn
19 Jun 20266.63 USD-1.5%5.60 USD9.99 USD1.09-14.593.9MOff
12 Jun 20266.73 USD0.9%5.61 USD10.00 USD1.08-12.393.5MOff
5 Jun 20266.67 USD1.7%5.62 USD10.00 USD1.14-12.683.8MOff
29 May 20266.56 USD7.7%5.62 USD10.02 USD1.24-19.353.2MOff
22 May 20266.09 USD-6.3%5.62 USD10.03 USD1.19-24.143.6MOff
15 May 20266.50 USD2.2%5.64 USD10.05 USD1.19-19.513.1MOff
8 May 20266.36 USD19.3%5.64 USD10.07 USD0.98-22.749.3MOff
1 May 20265.33 USD0.6%5.63 USD10.09 USD0.51-32.942.9MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.